Study guide

5.2 Antiepileptics & Neurologic Agents

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

5.2 Antiepileptics & Neurologic Agents

Key Takeaways Explain This Topic AI

First-line by seizure type: focal - carbamazepine, lamotrigine, or levetiracetam; generalized - valproate, levetiracetam, or lamotrigine; absence - ethosuximide

Carbamazepine is a potent CYP3A4 autoinducer (levels fall after 2-4 weeks), causes hyponatremia, and carries Stevens-Johnson risk in HLA-B*1502-positive patients

Phenytoin follows nonlinear (saturable) kinetics - small dose increases can cause disproportionate level jumps; toxicity presents as nystagmus, ataxia, and diplopia

Status epilepticus: buccal midazolam or IV lorazepam first-line, then a second-line agent such as IV phenytoin, levetiracetam, or valproate

Levodopa (given with carbidopa) remains the most effective Parkinson's drug but long-term use produces motor fluctuations and dyskinesias

Last updated: August 2026

Choosing an Antiepileptic by Seizure Type

Drug selection is driven by seizure classification, and this is a reliable exam angle:

  • Seizure type First-line options
  • Focal (partial) Carbamazepine, lamotrigine, levetiracetam (also oxcarbazepine, sodium valproate)
  • Generalized tonic-clonic Valproate, levetiracetam, lamotrigine (lamotrigine can worsen myoclonus)
  • Absence Ethosuximide (valproate if tonic-clonic coexists)

Valproate is the most effective agent for generalized epilepsies, but it is contraindicated in women of childbearing potential wherever an alternative exists because of teratogenicity (neural tube defects, neurodevelopmental harm); international regulators require a pregnancy-prevention program when it must be used.

Two cross-cutting points apply to almost all antiepileptics. First, pregnancy counseling : enzyme-inducing agents (carbamazepine, phenytoin) reduce hormonal contraceptive efficacy, and all women on antiepileptics who may conceive should receive high-dose folic acid (5 mg daily) preconception and through the first trimester, with the fewest effective agents at the lowest effective dose. Second, baseline and periodic monitoring matters: full blood count and liver function for carbamazepine and valproate (valproate causes hepatotoxicity, pancreatitis, and thrombocytopenia), and awareness that abrupt withdrawal of any antiepileptic can trigger rebound seizures - adherence counseling is a recurring pharmacist role.

  • The High-Yield Antiepileptics
  • Carbamazepine

Carbamazepine blocks voltage-gated sodium channels and is first-line for focal seizures and trigeminal neuralgia. Three facts dominate exam questions:

CYP3A4 autoinduction - it induces its own metabolism, so plasma concentrations fall over the first 2-4 weeks and the dose often needs upward adjustment; it also reduces the effectiveness of hormonal contraceptives, warfarin, and many other substrates.

Hyponatremia (SIADH-like) - check sodium if the patient becomes confused or lethargic.

HLA-B*1502 - patients of Han Chinese, Thai, and other Southeast Asian ancestry carrying this allele have a greatly elevated risk of Stevens-Johnson syndrome / toxic epidermal necrolysis ; screen before starting in at-risk populations.

Phenytoin

Phenytoin exhibits nonlinear (Michaelis-Menten) kinetics : once metabolizing enzymes saturate, elimination switches from first-order to zero-order , so a small dose increase (even 25-50 mg) can produce a large, disproportionate jump in plasma level. Target 10-20 mg/L. Signs of toxicity follow a roughly dose-related sequence: nystagmus first, then ataxia, diplopia, sedation, and encephalopathy . Chronic adverse effects include gingival hyperplasia (meticulous dental hygiene), hirsutism, coarsened facies, folate deficiency, and osteomalacia. Phenytoin is highly protein-bound and a potent enzyme inducer, creating many interactions; in hypoalbuminemia or renal failure, interpret total levels with an albumin correction or measure free drug. IV phenytoin must be given slowly (max 50 mg/min) because of hypotension and arrhythmia risk from its propylene glycol diluent.

Levetiracetam

Levetiracetam binds the synaptic vesicle protein SV2A, has minimal drug interactions, no required level monitoring, and renally-adjusted dosing - a convenient broad-spectrum option. Its characteristic drawback is behavioral adverse effects : irritability, agitation, depression, and occasionally psychosis, particularly in patients with prior psychiatric history.

Gabapentinoids

Gabapentin and pregabalin bind the alpha-2-delta subunit of voltage-gated calcium channels. They are used for focal seizure adjuncts but mainly for neuropathic pain ; both are renally cleared (dose-adjust in CKD), cause sedation and weight gain, and have recognized misuse and dependence potential, which matters for UAE controlled-medicine dispensing rules.

Status Epilepticus

Convulsive status epilepticus (seizure activity beyond 5 minutes) is a medical emergency treated in stages:

First-line - a benzodiazepine : IV lorazepam (or diazepam) in hospital; buccal midazolam or rectal diazepam out of hospital. Repeat once if the seizure continues.

Second-line - a longer-acting antiepileptic : IV phenytoin (or fosphenytoin), levetiracetam, or valproate - the ESETT trial showed these three are broadly equivalent.

Refractory status : general anesthesia with agents such as midazolam, propofol, or thiopental infusion in intensive care.

Parkinson's Disease

Parkinson's disease reflects dopaminergic loss in the substantia nigra. Levodopa , always combined with a peripheral dopa-decarboxylase inhibitor ( carbidopa or benserazide) to reduce peripheral side effects, remains the most effective symptomatic treatment. With long-term use most patients develop motor fluctuations - end-of-dose "wearing off" and unpredictable "on-off" phenomena - plus peak-dose dyskinesias . Other classes:

Dopamine agonists (pramipexole, ropinirole, rotigotine patch) - useful initial therapy in younger patients to delay levodopa; watch for impulse-control disorders (gambling, hypersexuality), somnolence, and hallucinations.

MAO-B inhibitors (selegiline, rasagiline, safinamide) - mild symptomatic benefit; avoid with SSRIs/pethidine because of serotonin syndrome risk.

COMT inhibitors (entacapone, opicapone) - extend levodopa's half-life to smooth wearing-off; entacapone discolors urine orange.

Anticholinergics (trihexyphenidyl) - help tremor in young patients but are avoided in the elderly (confusion, urinary retention).

Alzheimer's Disease

Donepezil (with rivastigmine and galantamine) is an acetylcholinesterase inhibitor for mild-to-moderate Alzheimer's disease; it modestly improves cognition without altering disease progression. Cholinergic adverse effects - nausea, diarrhea, bradycardia (caution with conduction disease), and vivid dreams - are class dose-limiting. Memantine , an NMDA-receptor antagonist, is used for moderate-to-severe disease and is better tolerated, with dizziness and confusion the main effects. Neither class is curative; pharmacist counseling on realistic expectations is examinable.

Multiple Sclerosis (Concept Level)

Multiple sclerosis is managed with disease-modifying therapies (interferon beta, glatiramer acetate, fingolimod, ocrelizumab, natalizumab) that reduce relapse frequency, plus acute relapses treated with high-dose IV methylprednisolone . For the DHA assessment, concept-level familiarity suffices: know that these agents modify disease course, that natalizumab carries progressive multifocal leukoencephalopathy risk, and that supportive drugs (e.g., baclofen for spasticity) manage symptoms.